Acute myeloid leukaemia - Pipeline Insight, 2024

Acute myeloid leukaemia - Pipeline Insight, 2024

DelveInsight’s, “Acute myeloid leukaemia - Pipeline Insight, 2024,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute myeloid leukaemia Understanding

Acute myeloid leukaemia: Overview

Acute Myeloid Leukemia (AML) (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but most often it quickly moves into the blood, as well. It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. Acute Myeloid Leukemia (AML) (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.

""Acute myeloid leukaemia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute myeloid leukaemia pipeline landscape is provided which includes the disease overview and Acute myeloid leukaemia treatment guidelines. The assessment part of the report embraces, in depth Acute myeloid leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute myeloid leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute myeloid leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Acute myeloid leukaemia.

Acute myeloid leukaemia Emerging Drugs Chapters

This segment of the Acute myeloid leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute myeloid leukaemia Emerging Drugs

• BST-236: BioSight

Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. The drug is currently in phase II stage of of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

• Uproleselan: GlycoMimetics

GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. The drug is currently in phase III stage of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

• MK-0482: Merck Sharp & Dohme LLC

MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts.

Further product details are provided in the report……..

Acute myeloid leukaemia: Therapeutic Assessment

This segment of the report provides insights about the different Acute myeloid leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acute myeloid leukaemia

There are approx. 150+ key companies which are developing the therapies for Acute myeloid leukaemia. The companies which have their Acute myeloid leukaemia drug candidates in the most advanced stage, i.e. phase III include, GlycoMimetics.

Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute myeloid leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute myeloid leukaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute myeloid leukaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute myeloid leukaemia drugs.

Acute myeloid leukaemia Report Insights

• Acute myeloid leukaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute myeloid leukaemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute myeloid leukaemia drugs?
• How many Acute myeloid leukaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute myeloid leukaemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute myeloid leukaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute myeloid leukaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioSight
• GlycoMimetics
• Sumitomo Pharma America, Inc.
• Menarini Group
• Telios Pharma, Inc.
• Kartos Therapeutics
• ImmunoGen, Inc.
• H3 Biomedicine Inc.
• Intellia Therapeutics
• Chongqing Precision Biotech Co., Ltd
• Innovent Biologics
• Betta Pharmaceuticals Co., Ltd.
• Maxinovel Pty., Ltd.
• Argenx
• Aptose Biosciences
• ALX Oncology Inc.
• Novartis
• Fujifilm Pharmaceuticals U.S.A., Inc.
• I-Mab Biopharma Co. Ltd.
• Akeso
• Gilead Sciences
• Kronos Bio
• Celgene
• Polaris Group
• Ryvu Therapeutics SA
• Kura Oncology, Inc.
• Sanofi
• Amgen
• BioTheryX, Inc.
• Arog Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp.
• Actinium Pharmaceuticals
• Moleculin Biotech
• Karyopharm Therapeutics Inc

Key Products

• BST-236
• Uproleselan
• BTX-A51
• Research programme: T-cell receptor based therapies
• MK-0482
• AMG 176
• KPT-9274
• Iomab-B
• Crenolanib besylate
• Liposomal Annamycin
• ARGX-110
• KO-539
• TJ011133
• SAR443579
• Magrolimab
• Sabatolimab
• FF-10101-01
• Lanraplenib
• evorpacept
• RVU120
• ADI-PEG 20
• CC-91633
• IMGN632
• HM43239
• DSP 5336
• MEN 1703
• AK117
• TL-895
• KRT-232
• MRX2843
• MAX-40279-01